Modern Anti-Tuberculosis Drugs and Their Classification. Part I: First-Line Drugs

L. A. Kаyukova, Elmira A. Berikova

2020

Full text Open access: Hybrid Metadata (CSL-JSON)
DOI 10.1007/s11094-020-02239-2
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

The historical classification (1993) of anti-tuberculosis drugs included three (I-III) lines that were subdivided into five groups (2006). The duration of treatment of drug-sensitive (DS) tuberculosis (TB) with first-line drugs is 6 – 12 months; of multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB with second-line drugs, 18 months and longer. The Directly Observed Treatment Short course (DOTS) and DOTS-Plus therapies are measures of world TB control. Based on the need for more effective treatment of MDR and XDR TB, the classification of 2016 introduced six groups (A-C and D1-D3) in connection with the development of new anti-TB drugs. The present review presents first-line preparations and their new derivatives possessing activity against DS and drug-resistant (DR) M. tuberculosis strains.